Skip to main content
Manuel Fernández Bruno on Muck Rack

Manuel Fernández Bruno

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Manuel Fernández

Contact Manuel Fernández, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial - Nature Communications

|
By Mariano Provencio, Begoña Campos, María Guirado, Laia Vilà, Rosario Garcia Campelo, Miriam Leandro Dorta, Sergio Vázquez Estévez, Asia Ferrández, M. Sala, Ana Ortega, Ana Blasco Verified, Amelia Insa, Maria Areses, Ivana Sullivan, Rafael Lopez, Virginia Calvo, Delvys Rodríguez-Abreu, Joaquim Bosch-Barrera, Ana López-Martín, Raquel Marsé, Laura A. Torrado, Julia Giner, Emilio Sánchez Saugar, Cristina Martinez-Toledo, Atocha Romero, Alberto Cruz-Bermúdez, Kirill Matskov, Manuel Fernández Bruno, Pilar Mediavilla
| Nature Verified
Abstract Unresectable stage III NSCLC standard treatment is chemo-radiotherapy (CT-RT) followed by immunotherapy (IO) with durvalumab. We investigated adding an induction phase with chemo-immunotherapy (ChIO). APOLO was a multicentre, single-arm, phase 2 trial (NCT04776447). Non-resectable stage IIIA–IIIC NSCLC patients received induction ChIO (atezolizumab + carboplatin + paclitaxel, for 3 cycles), followed by concurrent CT-RT (3 cycles), and IO maintenance (atezolizumab for 16 cycles).
Open in Who Shared Issue with article?
See all 1 articles